LB PHARMACEUTICALS INC (LBRX) SEC Filings

LB Pharmaceuticals Inc (LBRX) filed a prospectus supplement to its Form S-1, updating the prospectus to include a current report on the appointment of Joseph M. Miller as Chief Financial Officer effective September 2, 2026. The filing outlines his compensation terms and an inducement stock option grant.

Mr. Miller’s employment agreement provides a fixed base salary, target bonus opportunity, equity incentives outside the company’s 2025 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4), and defined severance and COBRA benefits upon certain terminations, including enhanced protection in connection with a change of control.

LB Pharmaceuticals Inc (LBRX) reported the appointment of Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, under an at-will employment agreement. He brings more than two decades of finance leadership experience at public biotech and pharmaceutical companies, including roles at Aurinia Pharmaceuticals and Avalo Therapeutics.

Mr. Miller will receive an initial annual base salary of $530,000, with a target bonus equal to 40% of base salary, and an option to purchase 200,000 shares of common stock granted as an inducement award subject to four-year vesting. The agreement provides enhanced severance and benefit continuation if he is terminated without cause or resigns for good reason, with additional cash and full equity acceleration in connection with a change of control. A concurrent press release highlights his experience guiding companies from pivotal data through commercialization as LB Pharmaceuticals approaches pivotal NOVA-2 Phase 3 trial results and potential commercialization of LB-102 for schizophrenia.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu report beneficial ownership of LB Pharmaceuticals Inc. common stock on an amended Schedule 13G. The reporting group is associated with 1,447,310 shares of common stock, representing 5.0% of the class.

The ownership percentage is based on 28,676,652 shares outstanding as of May 7, 2026, as reported by LB Pharmaceuticals Inc. Each reporting person states that they may be deemed to share voting and dispositive power over these shares through TCG Crossover Fund II and its general partner, and each disclaims beneficial ownership except to the extent of any pecuniary interest.

LB Pharmaceuticals Inc. filed a prospectus supplement to its Form S-1 resale registration, updating investors with its June 30, 2026 quarterly report. The registration relates to securities issued in a February 2026 private placement of 3,306,571 common shares and pre-funded warrants exercisable for up to 1,417,107 additional shares. As of June 30, 2026, the company held $327.8 million in cash, cash equivalents and marketable securities and reported total assets of $361.7 million. It recorded a six‑month net loss of $70.7 million, driven by $58.8 million in research and development spending and $17.2 million in general and administrative expenses as it advances its lead neuromedicine candidate LB‑102 through a Phase 3 schizophrenia trial and Phase 2 bipolar depression program. A subsequent July 2026 private placement raised an additional $150.0 million in gross proceeds.

LB Pharmaceuticals Inc. reported significantly higher operating spending as it advances its lead neuromedicine candidate LB‑102 through late-stage trials. For the six months ended June 30, 2026, the company recorded a net loss of $70.7 million versus $10.2 million a year earlier, driven mainly by research and development expenses of $58.8 million and general and administrative expenses of $17.2 million.

Cash, cash equivalents and marketable securities totaled $327.8 million at June 30, 2026, plus a subsequent July 2026 private placement that raised $150.0 million in gross proceeds. Management states these resources, including the July financing, are expected to fund operations beyond the second quarter of 2029 as LB‑102 progresses through Phase 3 in schizophrenia, Phase 2 in bipolar depression, and additional planned indications.

LB Pharmaceuticals reported second quarter 2026 results and a corporate update centered on its lead neuropsychiatric candidate LB-102. The pivotal Phase 3 NOVA-2 trial in schizophrenia is enrolling faster than expected, with topline data now projected in the first half of 2027, followed by a planned pre-NDA FDA meeting in the second half of 2027. Additional Phase 2 trials in bipolar depression and adjunctive major depressive disorder are ongoing or planned, with key readouts expected from 2028–2029.

Liquidity is a major focus: cash, cash equivalents and marketable securities totaled $327.8 million as of June 30, 2026, and together with proceeds from a recent $150.0 million private placement are expected to fund operations beyond the second quarter of 2029 through multiple clinical milestones. The company is using this capital to expand LB-102 into new neuropsychiatric indications.

The investment phase is driving significantly higher spending. Research and development expense rose to $44.1 million in the quarter from $2.4 million a year earlier, contributing to a quarterly net loss of $51.6 million versus $4.9 million in the prior-year period. For the first six months of 2026, net loss was $70.7 million. The balance sheet shows total assets of $361.7 million and stockholders’ equity of $332.3 million as of June 30, 2026, reflecting a well-capitalized but loss-making development-stage profile.

LB Pharmaceuticals Inc. received an insider report from Deep Track–affiliated entities. On 2026-07-30, Deep Track Biotechnology Master Fund, Ltd., a ten percent holder, purchased 286205.0000 Pre-Funded Warrants to buy LBRX common stock at $34.9399 per warrant, bringing its direct Pre-Funded Warrant position to 664649.0000. Each warrant is immediately exercisable at $0.0001 per share, does not expire, and is subject to a 9.99% beneficial ownership limitation. A separate indirect position of 93925.0000 Pre-Funded Warrants is reported as held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but disclaim beneficial ownership except to the extent of their pecuniary interests.

BlackRock, Inc. filed Amendment No. 1 reporting beneficial ownership of 1,796,543 shares of LB Pharmaceuticals Inc. common stock, representing 6.3% of the class as of June 30, 2026. BlackRock reports sole voting power over 1,771,160 shares and sole dispositive power over 1,796,543 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of LB Pharmaceuticals’ outstanding common shares.

LB Pharmaceuticals Inc. entered into a private placement with institutional investors to sell 3,577,560 shares of common stock and pre-funded warrants to purchase up to 715,513 shares. Shares are priced at $34.94 and the pre-funded warrants at $34.9399 with a de minimis exercise price of $0.0001 per share. The company expects approximately $150.0 million in gross proceeds, before expenses.

The pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership limits of 4.99% or 9.99%, adjustable up to 19.99% with notice. LB Pharmaceuticals plans to use the proceeds, together with existing cash, to expand development of LB-102 into additional indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and for working capital and general corporate purposes. A Registration Rights Agreement requires filing an S-3 resale registration for the shares and warrant shares within 90 days of closing and using reasonable best efforts to obtain effectiveness within 90 days of filing.